APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Disease Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Respiratory Disease Vaccine Market Analysis and Forecast 2026-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchRespiratory Disease Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Disease Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Disease Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Disease Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Disease Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Respiratory Disease Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Respiratory Disease Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Respiratory Disease Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Respiratory Disease Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Respiratory Disease Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Respiratory Disease Vaccine include Sanofi SA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., SINOVAC, Serum Institute of India Pvt. Ltd., Novavax, GSK plc. and Emergent BioSolutions Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Respiratory Disease Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Respiratory Disease Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Disease Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Respiratory Disease Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Respiratory Disease Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Respiratory Disease Vaccine sales, projected growth trends, production technology, application and end-user industry.

Respiratory Disease Vaccine Segment by Company

Sanofi SA

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Pfizer Inc.

SINOVAC

Serum Institute of India Pvt. Ltd.

Novavax

GSK plc.

Emergent BioSolutions Inc.

AstraZeneca

Respiratory Disease Vaccine Segment by Type

Live Attenuated

Inactivated

Others

Respiratory Disease Vaccine Segment by Application

Flu

Pneumonia

Others

Respiratory Disease Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Disease Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Respiratory Disease Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Respiratory Disease Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Respiratory Disease Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Respiratory Disease Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Live Attenuated Major Manufacturers Table 3. Inactivated Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Respiratory Disease Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Flu Major Manufacturers Table 7. Pneumonia Major Manufacturers Table 8. Others Major Manufacturers Table 9. Respiratory Disease Vaccine Industry Trends Table 10. Respiratory Disease Vaccine Industry Drivers Table 11. Respiratory Disease Vaccine Industry Opportunities and Challenges Table 12. Respiratory Disease Vaccine Industry Restraints Table 13. Global Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Respiratory Disease Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Respiratory Disease Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Respiratory Disease Vaccine Revenue Market Share by Region (2021-2026) Table 17. Global Respiratory Disease Vaccine Revenue Market Share by Region (2027-2032) Table 18. Global Respiratory Disease Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Respiratory Disease Vaccine Sales by Region (2021-2026) & (K Units) Table 20. Global Respiratory Disease Vaccine Sales by Region (2027-2032) & (K Units) Table 21. Global Respiratory Disease Vaccine Sales Market Share by Region (2021-2026) Table 22. Global Respiratory Disease Vaccine Sales Market Share by Region (2027-2032) Table 23. Global Respiratory Disease Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Respiratory Disease Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Respiratory Disease Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Respiratory Disease Vaccine Sales Market Share by Manufacturers (2021-2026) Table 27. Global Respiratory Disease Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Respiratory Disease Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Respiratory Disease Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Respiratory Disease Vaccine Manufacturers, Product Type & Application Table 31. Global Respiratory Disease Vaccine Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Respiratory Disease Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Respiratory Disease Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Respiratory Disease Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Respiratory Disease Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2026) Table 38. Global Respiratory Disease Vaccine Revenue Market Share by Type (2027-2032) Table 39. Global Respiratory Disease Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 41. Global Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 42. Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2026) Table 43. Global Respiratory Disease Vaccine Sales Market Share by Type (2027-2032) Table 44. Global Respiratory Disease Vaccine Price by Type (2021-2026) & (US$/Unit) Table 45. Global Respiratory Disease Vaccine Price by Type (2027-2032) & (US$/Unit) Table 46. Global Respiratory Disease Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Respiratory Disease Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Respiratory Disease Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2026) Table 50. Global Respiratory Disease Vaccine Revenue Market Share by Application (2027-2032) Table 51. Global Respiratory Disease Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 53. Global Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 54. Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2026) Table 55. Global Respiratory Disease Vaccine Sales Market Share by Application (2027-2032) Table 56. Global Respiratory Disease Vaccine Price by Application (2021-2026) & (US$/Unit) Table 57. Global Respiratory Disease Vaccine Price by Application (2027-2032) & (US$/Unit) Table 58. Sanofi SA Company Information Table 59. Sanofi SA Business Overview Table 60. Sanofi SA Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Sanofi SA Respiratory Disease Vaccine Product Portfolio Table 62. Sanofi SA Recent Development Table 63. Johnson & Johnson Services, Inc. Company Information Table 64. Johnson & Johnson Services, Inc. Business Overview Table 65. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio Table 67. Johnson & Johnson Services, Inc. Recent Development Table 68. Merck & Co., Inc. Company Information Table 69. Merck & Co., Inc. Business Overview Table 70. Merck & Co., Inc. Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio Table 72. Merck & Co., Inc. Recent Development Table 73. Pfizer Inc. Company Information Table 74. Pfizer Inc. Business Overview Table 75. Pfizer Inc. Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer Inc. Respiratory Disease Vaccine Product Portfolio Table 77. Pfizer Inc. Recent Development Table 78. SINOVAC Company Information Table 79. SINOVAC Business Overview Table 80. SINOVAC Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. SINOVAC Respiratory Disease Vaccine Product Portfolio Table 82. SINOVAC Recent Development Table 83. Serum Institute of India Pvt. Ltd. Company Information Table 84. Serum Institute of India Pvt. Ltd. Business Overview Table 85. Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio Table 87. Serum Institute of India Pvt. Ltd. Recent Development Table 88. Novavax Company Information Table 89. Novavax Business Overview Table 90. Novavax Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novavax Respiratory Disease Vaccine Product Portfolio Table 92. Novavax Recent Development Table 93. GSK plc. Company Information Table 94. GSK plc. Business Overview Table 95. GSK plc. Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. GSK plc. Respiratory Disease Vaccine Product Portfolio Table 97. GSK plc. Recent Development Table 98. Emergent BioSolutions Inc. Company Information Table 99. Emergent BioSolutions Inc. Business Overview Table 100. Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio Table 102. Emergent BioSolutions Inc. Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca Respiratory Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. AstraZeneca Respiratory Disease Vaccine Product Portfolio Table 107. AstraZeneca Recent Development Table 108. North America Respiratory Disease Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Respiratory Disease Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 111. North America Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 112. North America Respiratory Disease Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 113. North America Respiratory Disease Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 114. North America Respiratory Disease Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 115. North America Respiratory Disease Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 116. North America Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 117. North America Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 118. North America Respiratory Disease Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 119. North America Respiratory Disease Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 120. North America Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Respiratory Disease Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 122. North America Respiratory Disease Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 123. North America Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 124. North America Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 125. North America Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 126. North America Respiratory Disease Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 127. North America Respiratory Disease Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 128. United States Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 129. Canada Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 130. Mexico Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 131. Europe Respiratory Disease Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Respiratory Disease Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 134. Europe Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 135. Europe Respiratory Disease Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 136. Europe Respiratory Disease Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 137. Europe Respiratory Disease Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 138. Europe Respiratory Disease Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 139. Europe Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 140. Europe Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 141. Europe Respiratory Disease Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 142. Europe Respiratory Disease Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 143. Europe Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Respiratory Disease Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 145. Europe Respiratory Disease Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 146. Europe Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 147. Europe Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 148. Europe Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 149. Europe Respiratory Disease Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 150. Europe Respiratory Disease Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 151. Germany Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 152. France Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 153. U.K. Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 154. Italy Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 155. Russia Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 156. Spain Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 157. Netherlands Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 158. Switzerland Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 159. Sweden Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 160. Poland Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 161. China Respiratory Disease Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 162. China Respiratory Disease Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 163. China Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 164. China Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 165. China Respiratory Disease Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 166. China Respiratory Disease Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 167. China Respiratory Disease Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 168. China Respiratory Disease Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 169. China Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 170. China Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 171. China Respiratory Disease Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 172. China Respiratory Disease Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 173. Asia Respiratory Disease Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 174. Asia Respiratory Disease Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 175. Asia Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 176. Asia Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 177. Asia Respiratory Disease Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 178. Asia Respiratory Disease Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 179. Asia Respiratory Disease Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 180. Asia Respiratory Disease Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 181. Asia Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 182. Asia Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 183. Asia Respiratory Disease Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 184. Asia Respiratory Disease Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 185. Asia Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. Asia Respiratory Disease Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. Asia Respiratory Disease Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. Asia Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 189. Asia Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 190. Asia Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 191. Asia Respiratory Disease Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 192. Asia Respiratory Disease Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 193. Japan Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 194. South Korea Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 195. India Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 196. Australia Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 197. Taiwan Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 198. Southeast Asia Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 199. SAMEA Respiratory Disease Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 200. SAMEA Respiratory Disease Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 201. SAMEA Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 202. SAMEA Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 203. SAMEA Respiratory Disease Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 204. SAMEA Respiratory Disease Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 205. SAMEA Respiratory Disease Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 206. SAMEA Respiratory Disease Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 207. SAMEA Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 208. SAMEA Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 209. SAMEA Respiratory Disease Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 210. SAMEA Respiratory Disease Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 211. SAMEA Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. SAMEA Respiratory Disease Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. SAMEA Respiratory Disease Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. SAMEA Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 215. SAMEA Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 216. SAMEA Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 217. SAMEA Respiratory Disease Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 218. SAMEA Respiratory Disease Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 219. Brazil Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 220. Argentina Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 221. Chile Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 222. Colombia Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Peru Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 224. Saudi Arabia Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 225. Israel Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 226. UAE Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 227. Turkey Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 228. Iran Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 229. Egypt Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Table 230. Key Raw Materials Table 231. Raw Materials Key Suppliers Table 232. Respiratory Disease Vaccine Distributors List Table 233. Respiratory Disease Vaccine Customers List Table 234. Research Programs/Design for This Report Table 235. Authors List of This Report Table 236. Secondary Sources Table 237. Primary Sources List of Figures Figure 1. Respiratory Disease Vaccine Image Figure 2. Global Respiratory Disease Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Disease Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Live Attenuated Image Figure 5. Inactivated Image Figure 6. Others Image Figure 7. Global Respiratory Disease Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Respiratory Disease Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 9. Flu Image Figure 10. Pneumonia Image Figure 11. Others Image Figure 12. Global Respiratory Disease Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Figure 14. Global Respiratory Disease Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Respiratory Disease Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Respiratory Disease Vaccine Revenue Market Share by Region (2021-2032) Figure 17. Global Respiratory Disease Vaccine Sales (2021-2032) & (K Units) Figure 18. Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Respiratory Disease Vaccine Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Respiratory Disease Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. Europe Respiratory Disease Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. China Respiratory Disease Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Respiratory Disease Vaccine Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Respiratory Disease Vaccine Sales YoY (2021-2032) & (K Units) Figure 25. Global Respiratory Disease Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Respiratory Disease Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Respiratory Disease Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Respiratory Disease Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2032) Figure 31. Global Respiratory Disease Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Respiratory Disease Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2032) Figure 34. Global Respiratory Disease Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Respiratory Disease Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2032) Figure 37. Global Respiratory Disease Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Respiratory Disease Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2032) Figure 40. North America Respiratory Disease Vaccine Revenue Share by Type (2021-2032) Figure 41. North America Respiratory Disease Vaccine Sales Share by Type (2021-2032) Figure 42. North America Respiratory Disease Vaccine Revenue Share by Application (2021-2032) Figure 43. North America Respiratory Disease Vaccine Sales Share by Application (2021-2032) Figure 44. North America Respiratory Disease Vaccine Revenue Share by Country (2021-2032) Figure 45. North America Respiratory Disease Vaccine Sales Share by Country (2021-2032) Figure 46. Europe Respiratory Disease Vaccine Revenue Share by Type (2021-2032) Figure 47. Europe Respiratory Disease Vaccine Sales Share by Type (2021-2032) Figure 48. Europe Respiratory Disease Vaccine Revenue Share by Application (2021-2032) Figure 49. Europe Respiratory Disease Vaccine Sales Share by Application (2021-2032) Figure 50. Europe Respiratory Disease Vaccine Revenue Share by Country (2021-2032) Figure 51. Europe Respiratory Disease Vaccine Sales Share by Country (2021-2032) Figure 52. China Respiratory Disease Vaccine Revenue Share by Type (2021-2032) Figure 53. China Respiratory Disease Vaccine Sales Share by Type (2021-2032) Figure 54. China Respiratory Disease Vaccine Revenue Share by Application (2021-2032) Figure 55. China Respiratory Disease Vaccine Sales Share by Application (2021-2032) Figure 56. Asia Respiratory Disease Vaccine Revenue Share by Type (2021-2032) Figure 57. Asia Respiratory Disease Vaccine Sales Share by Type (2021-2032) Figure 58. Asia Respiratory Disease Vaccine Revenue Share by Application (2021-2032) Figure 59. Asia Respiratory Disease Vaccine Sales Share by Application (2021-2032) Figure 60. Asia Respiratory Disease Vaccine Revenue Share by Country (2021-2032) Figure 61. Asia Respiratory Disease Vaccine Sales Share by Country (2021-2032) Figure 62. SAMEA Respiratory Disease Vaccine Revenue Share by Type (2021-2032) Figure 63. SAMEA Respiratory Disease Vaccine Sales Share by Type (2021-2032) Figure 64. SAMEA Respiratory Disease Vaccine Revenue Share by Application (2021-2032) Figure 65. SAMEA Respiratory Disease Vaccine Sales Share by Application (2021-2032) Figure 66. SAMEA Respiratory Disease Vaccine Revenue Share by Country (2021-2032) Figure 67. SAMEA Respiratory Disease Vaccine Sales Share by Country (2021-2032) Figure 68. Respiratory Disease Vaccine Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Respiratory Disease Vaccine Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Live Attenuated
  • Inactivated
  • Others
Applications
  • Flu
  • Pneumonia
  • Others
Companies covered
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SINOVAC
  • Serum Institute of India Pvt. Ltd.
  • Novavax
  • GSK plc.
  • Emergent BioSolutions Inc.
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Respiratory Disease Vaccine Market by Type
  3. 1.2.1 Global Respiratory Disease Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Live Attenuated
  5. 1.2.3 Inactivated
  6. 1.2.4 Others
  7. 1.3 Respiratory Disease Vaccine Market by Application
  8. 1.3.1 Global Respiratory Disease Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Flu
  10. 1.3.3 Pneumonia
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Respiratory Disease Vaccine Market Dynamics
  1. 2.1 Respiratory Disease Vaccine Industry Trends
  2. 2.2 Respiratory Disease Vaccine Industry Drivers
  3. 2.3 Respiratory Disease Vaccine Industry Opportunities and Challenges
  4. 2.4 Respiratory Disease Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Respiratory Disease Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Respiratory Disease Vaccine Revenue by Region
  3. 3.2.1 Global Respiratory Disease Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Respiratory Disease Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Respiratory Disease Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Respiratory Disease Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Respiratory Disease Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Respiratory Disease Vaccine Sales by Region
  9. 3.4.1 Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Respiratory Disease Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Respiratory Disease Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Respiratory Disease Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Respiratory Disease Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Respiratory Disease Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Respiratory Disease Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Respiratory Disease Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Respiratory Disease Vaccine Sales by Manufacturers
  6. 4.2.1 Global Respiratory Disease Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Respiratory Disease Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Respiratory Disease Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Respiratory Disease Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Respiratory Disease Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Respiratory Disease Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Respiratory Disease Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Respiratory Disease Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Respiratory Disease Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Respiratory Disease Vaccine Tier 1, Tier 2, and Tier 3
5 Respiratory Disease Vaccine Market by Type
  1. 5.1 Global Respiratory Disease Vaccine Revenue by Type
  2. 5.1.1 Global Respiratory Disease Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Respiratory Disease Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Respiratory Disease Vaccine Sales by Type
  6. 5.2.1 Global Respiratory Disease Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Disease Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Respiratory Disease Vaccine Price by Type
6 Respiratory Disease Vaccine Market by Application
  1. 6.1 Global Respiratory Disease Vaccine Revenue by Application
  2. 6.1.1 Global Respiratory Disease Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Respiratory Disease Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Respiratory Disease Vaccine Sales by Application
  6. 6.2.1 Global Respiratory Disease Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Respiratory Disease Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Respiratory Disease Vaccine Price by Application
7 Company Profiles
  1. 7.1 Sanofi SA
  2. 7.1.1 Sanofi SA Company Information
  3. 7.1.2 Sanofi SA Business Overview
  4. 7.1.3 Sanofi SA Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi SA Respiratory Disease Vaccine Product Portfolio
  6. 7.1.5 Sanofi SA Recent Developments
  7. 7.2 Johnson & Johnson Services, Inc.
  8. 7.2.1 Johnson & Johnson Services, Inc. Company Information
  9. 7.2.2 Johnson & Johnson Services, Inc. Business Overview
  10. 7.2.3 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio
  12. 7.2.5 Johnson & Johnson Services, Inc. Recent Developments
  13. 7.3 Merck & Co., Inc.
  14. 7.3.1 Merck & Co., Inc. Company Information
  15. 7.3.2 Merck & Co., Inc. Business Overview
  16. 7.3.3 Merck & Co., Inc. Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio
  18. 7.3.5 Merck & Co., Inc. Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. Respiratory Disease Vaccine Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 SINOVAC
  26. 7.5.1 SINOVAC Company Information
  27. 7.5.2 SINOVAC Business Overview
  28. 7.5.3 SINOVAC Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 SINOVAC Respiratory Disease Vaccine Product Portfolio
  30. 7.5.5 SINOVAC Recent Developments
  31. 7.6 Serum Institute of India Pvt. Ltd.
  32. 7.6.1 Serum Institute of India Pvt. Ltd. Company Information
  33. 7.6.2 Serum Institute of India Pvt. Ltd. Business Overview
  34. 7.6.3 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio
  36. 7.6.5 Serum Institute of India Pvt. Ltd. Recent Developments
  37. 7.7 Novavax
  38. 7.7.1 Novavax Company Information
  39. 7.7.2 Novavax Business Overview
  40. 7.7.3 Novavax Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Novavax Respiratory Disease Vaccine Product Portfolio
  42. 7.7.5 Novavax Recent Developments
  43. 7.8 GSK plc.
  44. 7.8.1 GSK plc. Company Information
  45. 7.8.2 GSK plc. Business Overview
  46. 7.8.3 GSK plc. Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GSK plc. Respiratory Disease Vaccine Product Portfolio
  48. 7.8.5 GSK plc. Recent Developments
  49. 7.9 Emergent BioSolutions Inc.
  50. 7.9.1 Emergent BioSolutions Inc. Company Information
  51. 7.9.2 Emergent BioSolutions Inc. Business Overview
  52. 7.9.3 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio
  54. 7.9.5 Emergent BioSolutions Inc. Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Respiratory Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Respiratory Disease Vaccine Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America Respiratory Disease Vaccine Market Size by Type
  2. 8.1.1 North America Respiratory Disease Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Respiratory Disease Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Respiratory Disease Vaccine Price by Type (2021-2032)
  5. 8.2 North America Respiratory Disease Vaccine Market Size by Application
  6. 8.2.1 North America Respiratory Disease Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Respiratory Disease Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Respiratory Disease Vaccine Price by Application (2021-2032)
  9. 8.3 North America Respiratory Disease Vaccine Market Size by Country
  10. 8.3.1 North America Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Respiratory Disease Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Respiratory Disease Vaccine Market Size by Type
  2. 9.1.1 Europe Respiratory Disease Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Respiratory Disease Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Respiratory Disease Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Respiratory Disease Vaccine Market Size by Application
  6. 9.2.1 Europe Respiratory Disease Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Respiratory Disease Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Respiratory Disease Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Respiratory Disease Vaccine Market Size by Country
  10. 9.3.1 Europe Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Respiratory Disease Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Respiratory Disease Vaccine Market Size by Type
  2. 10.1.1 China Respiratory Disease Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Respiratory Disease Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Respiratory Disease Vaccine Price by Type (2021-2032)
  5. 10.2 China Respiratory Disease Vaccine Market Size by Application
  6. 10.2.1 China Respiratory Disease Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Respiratory Disease Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Respiratory Disease Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Respiratory Disease Vaccine Market Size by Type
  2. 11.1.1 Asia Respiratory Disease Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Respiratory Disease Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Respiratory Disease Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Respiratory Disease Vaccine Market Size by Application
  6. 11.2.1 Asia Respiratory Disease Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Respiratory Disease Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Respiratory Disease Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Respiratory Disease Vaccine Market Size by Country
  10. 11.3.1 Asia Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Respiratory Disease Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Respiratory Disease Vaccine Market Size by Type
  2. 12.1.1 SAMEA Respiratory Disease Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Respiratory Disease Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Respiratory Disease Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Respiratory Disease Vaccine Market Size by Application
  6. 12.2.1 SAMEA Respiratory Disease Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Respiratory Disease Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Respiratory Disease Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Respiratory Disease Vaccine Market Size by Country
  10. 12.3.1 SAMEA Respiratory Disease Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Respiratory Disease Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Respiratory Disease Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Respiratory Disease Vaccine Value Chain Analysis
  2. 13.1.1 Respiratory Disease Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Respiratory Disease Vaccine Production Mode & Process
  6. 13.2 Respiratory Disease Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Respiratory Disease Vaccine Distributors
  9. 13.2.3 Respiratory Disease Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst